Versant Capital Management, Inc Dyne Therapeutics, Inc. Call Options Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
210Shares Held
123MCall Options Held
36.5KPut Options Held
16.7K-
Ra Capital Management, L.P. Boston, MA9.71MShares$113 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$110 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$106 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$88.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$85.8 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $602M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...